← Back to searchRecruitingRecruiting
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034 · Reunion Neuroscience Inc
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses
About this study
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Eligibility criteria
Inclusion Criteria:
* Has a ≥4 week history of AjD as defined by DSM-5-TR with either depressed mood, or mixed anxiety and depressed mood confirmed by clinical interview with evidence that the AjD was instigated by one of the following medical illnesses (e.g., diagnosis, impact, management, recurrence, prognosis): Cancer, ALS, MS, PD or IPF
* Is sufficiently ambulatory and capable of self care as necessary to complete study procedures
* Has normal cognitive function
* Is on stable use of antidepressants or psychotherapy, or is willing to delay use until the end of study
* If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant
* Is willing and able to comply with the conditions and requirements of the study
Exclusion Criteria:
* Has a significant risk of suicide
* Has active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
* Has active or a history of central nervous system malignancy
* Has other medically significant conditions rendering unsuitability for the study
* Has used or will need to use prohibited medications or therapies
* Has a known sensitivity or intolerance to study intervention or potential rescue medications
Study design
Enrollment target: 100 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2025-07-30
Estimated completion: 2026-12
Last updated: 2026-03-16
Interventions
Drug: RE104 for Injection
Primary outcomes
- • RE104 30 mg versus RE104 1.5 mg change from baseline in MADRS total score (Day 7)
Sponsor
Reunion Neuroscience Inc · industry
Contacts & investigators
ContactMark Pollack, Chief Medical Officer · contact · info@reunionneuro.com · 1-888-880-REUN
InvestigatorMark Pollack, Chief Medical Officer · study_director, Reunion Neuroscience Inc
All locations (25)
UAB, Psychiatry and Behavioral NeurologyRecruiting
Birmingham, Alabama, United States
University of ArizonaRecruiting
Tucson, Arizona, United States
Kadima Neuropsychiatry InstituteRecruiting
San Diego, California, United States
Providence Medical FoundationRecruiting
Santa Rosa, California, United States
University of ColoradoRecruiting
Aurora, Colorado, United States
University of South Florida, Department of Psychiatry and Behavioral NeuroscienceRecruiting
Tampa, Florida, United States
Emory UniversityRecruiting
Atlanta, Georgia, United States
Hawaii Pacific NeuroscienceRecruiting
Honolulu, Hawaii, United States
Rush University Medical CenterRecruiting
Chicago, Illinois, United States
LSU Health ShreveportRecruiting
Shreveport, Louisiana, United States
Sunstone Therapies, PCRecruiting
Rockville, Maryland, United States
Sheppard PrattRecruiting
Towson, Maryland, United States
Dana Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
Henry Ford HealthRecruiting
Novi, Michigan, United States
University of New Mexico, School of MedicineRecruiting
Albuquerque, New Mexico, United States
NYU Langone Center for Psychedelic MedicineRecruiting
New York, New York, United States
University of North Carolina at Chapel HillRecruiting
Chapel Hill, North Carolina, United States
Cleveland ClinicRecruiting
Cleveland, Ohio, United States
The Ohio State University, Department of PsychiatryRecruiting
Columbus, Ohio, United States
University of PennsylvaniaRecruiting
Philadelphia, Pennsylvania, United States
Alliance for Multispecialty Research ClinicalRecruiting
Knoxville, Tennessee, United States
Dell Medical School, University of Texas at AustinRecruiting
Austin, Texas, United States
Cedar Clinical Research Inc.Recruiting
Draper, Utah, United States
UVA Center for Psychiatric Clinical ResearchRecruiting
Charlottesville, Virginia, United States
Seattle Neuropsychiatric Treatment CenterRecruiting
Seattle, Washington, United States